SynthesisMedicine2025
Interrelationship between PQ exposure and Parkinson disease: A systematic review and meta-analysis.
Synthesis in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A novel rat model of body first subtype of Parkinson's disease.bioRxiv : the preprint server for biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundSome studies have conflicting findings, suggesting that PQ has no association with the progression of Parkinson disease (PD). This meta-analysis aimed to investigate the impact of PQ on the incidence of PD.
methodsA computerized search was conducted in Pubmed, Embase, Cochrane, Web of Science, and Scopus for literature on factors influencing DEACMP from their inception to October 2023. Statistical analyses and meta-analyses were performed using STATA 17.0 and RevMan 5.4 software, respectively.
resultsA total of 181 articles were retrieved. 14 articles were included, comprising 4731 PD cases and 205,129 control cases. In case-control studies, the proportion of PQ exposure in the PD group was relatively high, with an odds ratio (OR) of 1.47 (95% confidence interval [CI]: 1.25, 1.72; I2 = 2%, P < .00001). In cohort studies, the PD group showed a relatively high proportion of PQ exposure, with an OR of 0.81 (95% CI: 0.71-0.92; I2 = 0%, P = .001). Additionally, subgroup analyses were conducted based on the study area. Studies from the United States and Canada indicated that the proportion of PQ exposure in the PD group was relatively high, with an OR of 1.36 (95% CI: 1.12-1.67; I2 = 10%, P = .002). In addition, the occupational exposure analysis showed that the proportion of PQ exposure in the PD group was higher, with an OR of 0.83 (95% CI: 0.71-0.99; I2 = 10%, P = .03). The environmental exposure analysis indicated a tendency towards a higher proportion of PQ exposure in the PD group, with an OR of 2.37 (95% CI: 0.98-5.73; I2 = 9%, P = .06). The mixed exposure analysis revealed a significantly higher proportion of PQ exposure in the PD group, with an OR of 1.47 (95% CI: 1.25-1.73; I2 = 0%, P < .0001).
conclusionsThis study demonstrates that PQ exposure does not obviously increase the incidence of PD. However, factors such as gender, exposure conditions, and regional differences may affect the incidence of PD induced by PQ exposure. Further clarification is required regarding the impact of paraquat exposure on PD. Simultaneously, efforts should be made to prohibit or reduce the use of and exposure to paraquat.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.